Publications by authors named "Maria-Jose Terol"

Article Synopsis
  • This study aims to create predictive models for treatment outcomes in patients with relapsed/refractory B-cell lymphoma undergoing CAR-T therapy by analyzing imaging data and clinical information.
  • It includes a cohort of 65 patients, utilizing imaging features from PET/CT scans to assess treatment response, overall survival, progression-free survival, and neurotoxicity risk associated with the therapy.
  • The results demonstrated that combining imaging features with clinical data significantly enhances prediction accuracy for treatment-related outcomes, highlighting the importance of metabolic tumor volume (MTV) in stratifying patient prognosis.
View Article and Find Full Text PDF
Article Synopsis
  • A phase 2 clinical trial evaluated tipifarnib, a drug for treating relapsed/refractory peripheral T-cell lymphoma (PTCL), involving 65 adult patients with various subtypes, predominantly angioimmunoblastic T-cell lymphoma (AITL).
  • The results showed an overall objective response rate (ORR) of 39.7%, with a higher ORR of 56.3% specifically in AITL patients; median progression-free survival (PFS) was 3.5 months overall.
  • While hematologic adverse events were observed (like neutropenia and thrombocytopenia), they were manageable, and 60% of responders had mutations linked to potential treatment sensitivity
View Article and Find Full Text PDF

Background: BTK inhibitors have been concurrently administered with anti-CD20 monoclonal antibodies (mAbs) in chronic lymphocytic leukemia (CLL). However, the optimal regimen for combining these two drugs remains pending.

Methods: This multi-center phase 2 study aimed to analyze whether consolidation with ofatumumab improved the response in patients with CLL receiving front-line treatment with ibrutinib.

View Article and Find Full Text PDF

Background: Immune effector cell-associated neurotoxicity syndrome (ICANS) is common after chimeric antigen receptor T-cell (CAR-T) therapy.

Objective: This study aimed to assess the impact of preinfusion electroencephalography (EEG) abnormalities and EEG findings at ICANS onset for predicting ICANS risk and severity in 56 adult patients with refractory lymphoma undergoing CAR-T therapy.

Study Design: EEGs were conducted at the time of lymphodepleting chemotherapy and shortly after onset of ICANS.

View Article and Find Full Text PDF

Torque Teno Virus (TTV) is a single-stranded circular DNA virus which has been identified as a surrogate marker of immune competence in transplantation. In this study we investigated the dynamics of plasma TTV DNAemia in 79 adult patients undergoing chimeric antigen receptor T-cell (CAR-T) therapy for relapsed or refractory large B-cell lymphoma, also evaluating the impact of TTV on immunotoxicities, response and survival outcomes. After lymphodepleting therapy, TTV DNA load was found to decrease slightly until reaching nadir around day 10, after which it increased steadily until reaching maximum load around day 90.

View Article and Find Full Text PDF

In the pre-chimeric antigen receptor T cell (CAR-T) therapy era, the SCHOLAR-1 study identified a group of patients with refractory aggressive B cell lymphoma (ABCL) with particularly poor prognoses. We recently published our real-world data from Spain, focused on this SCHOLAR-1 refractory group, and compared patients who underwent CAR-T therapy with the previous standard of care. In this study, we found that the efficacy of CAR-T therapy in refractory patients, in terms of progression-free survival (PFS) and overall survival (OS), was superior to that of the treatments available in the pre-CAR-T era.

View Article and Find Full Text PDF

High dose-intensive or infusional intermediate-dose immunochemotherapy is highly effective treatment for Burkitt lymphoma irrespective of human immunodeficiency virus (HIV) infection. However, toxicities of these regimens are relevant, especially in older adults and elderly patients. The prospective multicenter BURKIMAB14 trial included four to six blocks of immunochemotherapy according to stage (localized: 1 and 2 non-bulky; advanced: 2 bulky, 3, 4) and age, with dose reduction in patients >55 years old.

View Article and Find Full Text PDF
Article Synopsis
  • A study investigated whether monitoring Torque Teno virus (TTV) DNA levels could help predict infectious events in hematological patients treated with ibrutinib or ruxolitinib.
  • The research involved 41 patients and tracked TTV and Cytomegalovirus (CMV) DNA loads over time, finding that TTV levels increased in ibrutinib-treated patients but had no predictive value for CMV infections.
  • The results suggested that TTV monitoring is not a reliable indicator for CMV DNAemia or T-cell responses, highlighting the need for further research with larger patient groups.
View Article and Find Full Text PDF

The aims of our study were to analyse compliance with the 2014 GELTAMO SMZL Guidelines, in patients with splenic marginal zone lymphoma (SMZL), and to evaluate the outcome according to the HPLLs/ABC-adapted therapeutic strategy. Observational prospective multicenter study of 181 SMZL patients diagnosed between 2014 and 2020. Lymphoma-specific survival (LSS), composite event-free survival (CEFS) and response rates were assessed.

View Article and Find Full Text PDF
Article Synopsis
  • * A study assessed the ability of F-FDG PET/CT imaging features and clinical and genomic data to predict patients' responses to initial treatment, finding that a combined model significantly improved prediction accuracy.
  • * Results showed that the best prediction metrics came from a model that included genomic data, with specific imaging features related to lesion distribution also playing a critical role in determining treatment response.
View Article and Find Full Text PDF

The kinetics of SARS-CoV-2 reactive IgG antibodies after full vaccination and booster in allogeneic and autologous stem cell transplantation (allo-HSCT, ASCT) and chimeric antigen receptor T-cell therapy (CAR-T) are of utmost importance for estimating risk of infection. A prospective multicenter registry-based cohort study, conducted from December 2020 to July 2022 was used to analyze antibody waning over time, booster effect and the relationship of antibody response and breakthrough infection in 572 recipients (429 allo-HSCT, 121 ASCT and 22 CAR-T cell therapy). A significant decline in antibody titers was observed at 3 and 6 months after full vaccination in recipients without pre-vaccine SARS-CoV-2 infection, whereas recipients infected prior to vaccination showed higher and stable antibody titers over time.

View Article and Find Full Text PDF

Recent evidence suggests that the prognostic impact of gene mutations in patients with chronic lymphocytic leukemia (CLL) may differ depending on the immunoglobulin heavy variable (IGHV) gene somatic hypermutation (SHM) status. In this study, we assessed the impact of nine recurrently mutated genes (BIRC3, EGR2, MYD88, NFKBIE, NOTCH1, POT1, SF3B1, TP53, and XPO1) in pre-treatment samples from 4580 patients with CLL, using time-to-first-treatment (TTFT) as the primary end-point in relation to IGHV gene SHM status. Mutations were detected in 1588 (34.

View Article and Find Full Text PDF

Backgound: In the workup of follicular lymphoma (FL), bone marrow biopsy (BMB) assessment is a key component of FLIPI and FLIPI2, the most widely used outcome scores. During the previous decade, several studies explored the role of FDG-PET/CT for detecting nodal and extranodal disease, with only one large study comparing both techniques.

Methods: The aim of our study was to evaluate the diagnostic accuracy and the prognostic impact of both procedures in a retrospective cohort of 299 FL patients with both tests performed at diagnosis.

View Article and Find Full Text PDF
Article Synopsis
  • The study focuses on aggressive B-cell non-Hodgkin lymphoma (B-NHL) in HIV patients, specifically exploring its characteristics according to the 2017 WHO classification.
  • Researchers analyzed 75 cases using various techniques to evaluate genetic features like MYC, BCL2, and BCL6 status, as well as to assess their influence on prognosis.
  • Findings indicate that while certain genetic rearrangements are similar in HIV-positive patients and the general population, a lower frequency of BCL2 rearrangements and specific coexpressions (MYC and BCL2 in DLBCL, MUM1 in Burkitt-like lymphoma) are linked to worse outcomes for those with HIV.
View Article and Find Full Text PDF

Real-world evidence comparing the efficacy of chimeric antigen receptor (CAR) T-cell therapy against that of the previous standard of care (SOC) for refractory large B-cell lymphoma (LBCL) is scarce. We retrospectively collected data from patients with LBCL according to SCHOLAR-1 criteria treated with commercial CAR T-cell therapy in Spain (204 patients included and 192 treated, 101 with axicabtagene ciloleucel [axi-cel], and 91 with tisagenlecleucel [tisa-cel]) and compared the results with a historical refractory population of patients (n = 81) obtained from the GELTAMO-IPI study. We observed superior efficacy for CAR-T therapy (for both axi-cel and tisa-cel) over pSOC, with longer progression-free survival (PFS) (median of 5.

View Article and Find Full Text PDF

Prior studies of antibody response after full SARS-CoV-2 vaccination in hematological patients have confirmed lower antibody levels compared to the general population. Serological response in hematological patients varies widely according to the disease type and its status, and the treatment given and its timing with respect to vaccination. Through probabilistic machine learning graphical models, we estimated the conditional probabilities of having detectable anti-SARS-CoV-2 antibodies at 3-6 weeks after SARS-CoV-2 vaccination in a large cohort of patients with several hematological diseases (n= 1166).

View Article and Find Full Text PDF

Background: To investigate the multi-drug resistant bacteria (MDRB) colonization rate in hematological patients hospitalized for any cause using a multi-body-site surveillance approach, and determine the extent to which this screening strategy helped anticipate MDRB bloodstream infections (BSI).

Methods: Single-center retrospective observational study including 361 admissions documented in 250 adult patients. Surveillance cultures of nasal, pharyngeal, axillary and rectal specimens (the latter two combined) were performed at admission and subsequently on a weekly basis.

View Article and Find Full Text PDF

Chronic Lymphocytic Leukemia (CLL) is a hematological malignancy characterized by uncontrolled proliferation of B-cells and severe immune dysfunction. Chemo(immuno)therapies (CIT) have traditionally aimed to reduce tumor burden without fully understanding their effects on the immune system. As a consequence, CIT are usually associated with higher risk of infections, secondary neoplasms and autoimmune disorders.

View Article and Find Full Text PDF

Background: Ibrutinib demonstrated remarkable efficacy and favorable tolerability in patients with untreated or relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), including those with high-risk genetic alterations. The IBRORS-CLL study assessed the characteristics, clinical management and outcome of CLL patients receiving ibrutinib in routine clinical practice in Spain.

Patients: Observational, retrospective, multicenter study in CLL patients who started single-agent ibrutinib as first-line treatment or at first or second relapse between January 2016 and January 2019.

View Article and Find Full Text PDF

This is a randomized phase-2 trial aimed to compare consolidation vs. maintenance in untreated patients with follicular lymphoma (FL) responding to induction. 146 patients were enrolled from 25 Spanish institutions (ZAR2007; ClinicalTrials.

View Article and Find Full Text PDF

A PHP Error was encountered

Severity: Notice

Message: fwrite(): Write of 34 bytes failed with errno=28 No space left on device

Filename: drivers/Session_files_driver.php

Line Number: 272

Backtrace:

A PHP Error was encountered

Severity: Warning

Message: session_write_close(): Failed to write session data using user defined save handler. (session.save_path: /var/lib/php/sessions)

Filename: Unknown

Line Number: 0

Backtrace: